By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS


Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





Company News
FDA Approves Bristol-Myers Squibb Company (BMY)’s Evotaz™ (Atazanavir And Cobicistat) For The Treatment Of HIV-1 Infection In Adults 1/30/2015 6:06:45 AM
FDA Green Lights Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ) HIV Pills 1/30/2015 6:03:28 AM
Celldex Therapeutics, Inc. (CLDX) And Bristol-Myers Squibb Company (BMY) Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo® In Advanced Refractory Solid Tumors 1/29/2015 7:36:47 AM
Diagnostics For All Appoints Fran Heller, Former Bristol-Myers Squibb Company (BMY) Senior Executive, To Board Of Directors 1/26/2015 7:38:40 AM
Bristol-Myers Squibb Company (BMY) Names Caforio As New CEO Effective May 5 1/20/2015 3:59:29 PM
J.P. Morgan: Five Prime Therapeutics, Inc. (FPRX) CEO Says Experimental Drug to Head Into Six New Tumor Trials Via Bristol-Myers Squibb Company (BMY) 1/15/2015 1:19:13 PM
Bristol-Myers Squibb Company (BMY) And Eli Lilly (LLY) Enter Clinical Collaboration Agreement To Evaluate Opdivo (Nivolumab) In Combination With Galunisertib In Advanced Solid Tumors 1/13/2015 7:34:32 AM
Bristol-Myers Squibb Company (BMY) Release: CheckMate -017, A Phase 3 Study Of Opdivo (Nivolumab) Compared To Docetaxel In Patients With Second-Line Squamous Cell Non-Small Cell Lung Cancer, Stopped Early 1/12/2015 2:41:08 PM
Seattle Genetics, Inc. (SGEN) And Bristol-Myers Squibb Company (BMY) Announce Clinical Collaboration To Evaluate Combination Of Adcetris® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Hematologic Malignancies 1/12/2015 11:20:12 AM
Bristol-Myers Squibb Company (BMY) Study Halted After Opdivo Meets Efficacy Endpoint 1/12/2015 5:59:50 AM
12345678910...
//-->